Market Pulse: Glaxo study: Arixtra as effective as Lovenox
5th Sep 2005, 11:36 GMT
GlaxoSmithKline said a study presented at the European Society of Cardiology meeting in Stockholm showed that Arixtra was as effective in preventing death, myocardial infarction and refractory ischaemia at 9 days than Sanofi-Aventis' Lovenox/Clexane.
Latest news from Business of Healthcare News from myHealthcareNews.com:
- Alliance Names New COO
- NHCAA to Award Those Who Fight and Expose the Deadly Side of Health Care Fraud
- More Than 2 mln Cancer Patients Treated with BrainLAB m3 Shaped Beam Radiosurgery
- PA's Continuing Trend Towards Total Body Reconstruction Keeps Consumers Demanding Comprehensive Direct-To-Consumer-Education (DTCE )
- Dr Farzad Yaghouti of Global Laser Vision San Diego Wins 'Best Lasik Surgeon 2006'
- 1st Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Medical Mutual of OH Financial Investigator Wins Top Nat'l Fraud-Fighting Award
- Intelligent Medical Objects and Bond Technologies Sign Multi-year Agreement
- M-CARE's Medicaid Plan Recognized as One of the Top Health Plans by US News & World Report/NCQA
- Fitch: MCH rates 'A-' on bonds